Retro Biosciences developed RTR242 as a brain-penetrant small molecule intended to restore lysosomal acidity, which many enzymes need to break down cellular waste. This is a separate programme from Retro’s work on reprogramming factors.
An Australian registry lists its first-in-human study as ACTRN12625001274460. Retro says dosing began in 2025. The trial measures safety, tolerability and pharmacokinetics in healthy adults.
The proposed mechanism is worth testing in neurodegeneration, but the present study cannot establish a treatment effect in Alzheimer’s disease.
The mechanism
Autophagy delivers proteins, organelles and other material to lysosomes for breakdown. Many lysosomal enzymes depend on an acidic environment. Defects in this system are implicated in neurodegenerative disease, where long-lived neurons must maintain proteins and organelles over decades.
Retro describes RTR242 as an oral compound that enters the brain and restores lysosomal acidity. Its publicly available evidence does not yet include a complete peer-reviewed molecule-specific pharmacodynamic dataset.
Human evidence
The registered trial is randomised, double-blind and placebo-controlled, with single and multiple ascending doses in healthy adults. Researchers monitor adverse events, blood tests, vital signs, electrocardiograms and pharmacokinetics.
As of 24 October 2026, no published human results demonstrate improved cognition, delayed dementia or added lifespan. Later studies would need to measure these outcomes directly.
Studies and experimental evidence
RTR242 Phase 1, ACTRN12625001274460
- Design
- Randomised, double-blind, placebo-controlled single- and multiple-ascending-dose study
- Population or model
- Healthy adults in Australia
- Sample size
- Planned multiple cohorts; refer to current registry for enrolment
- Comparison
- Matching placebo
- Duration
- Single doses and short multiple-dose cohorts, with follow-up
- Outcome
- Safety, tolerability and pharmacokinetics
Study registered; developer reports first dosing in 2025
Not an Alzheimer’s efficacy trial; no posted peer-reviewed efficacy outcomes
Funding and interests: Retro Biosciences sponsorship
RTR242 programme mechanism
- Design
- Developer description of drug mechanism and early research
- Population or model
- Preclinical systems not fully detailed in checked public material
- Sample size
- Not publicly specified
- Comparison
- Not publicly specified
- Duration
- Not publicly specified
- Outcome
- Lysosomal acidity and cellular recycling
Developer states compound is designed to restore lysosomal acidity
Full molecule-specific experimental data not provided in reviewed sources
Funding and interests: Retro Biosciences
Development history
First-in-human dosing reported
Retro says RTR242 reached first-in-human dosing during 2025; no efficacy outcome follows from dosing alone.
Phase 1 study registered
Australian registry lists randomised single- and multiple-ascending-dose testing in healthy volunteers.
Clinical development confirmed
Retro’s financing and scientific update identifies RTR242 as its clinical-stage autophagy candidate.
Trial registry updated
Australian registry records amendments to the Phase 1 study; registry update is not a result readout.
Unresolved questions
- Which measured changes in lysosomal pH and autophagic flux can be demonstrated at doses tolerated in humans?
- What central-nervous-system exposure and target engagement will be demonstrated?
- Will larger or repeated doses show liver, neurological or other safety liabilities?
- What disease population and controlled endpoint would be used in a later efficacy trial?
- Is any effect sustained after treatment stops?
The next useful results will be Phase 1 safety, exposure and target-engagement data. A later controlled trial would need to assess clinical benefit in a defined patient population.
Sources
- Trial registry · 17 Nov 2025RTR242 Phase 1 ascending dose study ACTRN12625001274460
Randomised double-blind placebo-controlled first-in-human study in healthy adults; registration updated September 2026; no published clinical benefit result.
Checked 24 Oct 2026 - Company disclosure · Date not statedRetro Biosciences science pipeline
Retro describes RTR242 as brain-penetrant oral compound intended to restore lysosomal acidity; mechanism and indication are developer claims.
Checked 24 Oct 2026 - Company disclosure · 22 May 2026Retro Biosciences: Next Phase
Retro confirms RTR242 entered Phase I in 2025; its ten-year healthspan ambition is not a clinical result.
Checked 24 Oct 2026
Dr T Smith, organic chemist and science educator. Review date: 24 Oct 2026. Corrections information.